Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

NACompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

March 17, 2021

Study Completion Date

October 27, 2023

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

AHCL insulin pump system

670G 4.0 system with GS3; 780G system with G4S (continued access phase);

Trial Locations (17)

30076

Southeastern Endocrine, Roswell

30318

Atlanta Diabetes Associates, Atlanta

33613

University of South Florida, Tampa

38133

AM Diabetes & Endocrinology Center, Bartlett

55416

International Diabetes Center, Minneapolis

72211

Arkansas Diabetes and Endocrinology Center, Little Rock

78229

Diabetes and Glandular Disease Clinic, San Antonio

78681

Texas Endocrinology, Austin

80045

Barbara Davis Center - Adults, Aurora

Barbara Davis Center - Pediatric, Aurora

83404

Rocky Mountain Diabetes Center, Idaho Falls

90505

SoCal Diabetes, Torrance

92037

Scripps Whittier Diabetes Institute, La Jolla

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Clinical Research, Renton

98105

Seattle Children's Hospital and Medical Center, Seattle

06511

Yale Diabetes Research Program, New Haven

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY

NCT03959423 - Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System | Biotech Hunter | Biotech Hunter